Poly(2‐Hydroxyethyl Methacrylate) Hydrogel‐Based Microneedles for Metformin Release

The release of metformin, a drug used in the treatment of cancer and diabetes, from poly(2‐hydroxyethyl methacrylate), pHEMA, hydrogel‐based microneedle patches is demonstrated in vitro. Tuning the composition of the pHEMA hydrogels enables preparation of robust microneedle patches with mechanical p...

Full description

Saved in:
Bibliographic Details
Published inGlobal challenges Vol. 7; no. 8; pp. 2300002 - n/a
Main Authors Sharma, Manoj B., Kap, Özlem, Abdelmohsen, Hend A. M., Ashton, Mark D., Harper, Garry R., Firlak, Melike, Aaltonen, Jasmine E., Bolland, Kerry A., Bragg, Ryan, Deeley, Sarah, Francis, Ella, Kazi, Nahin, Mapley, Bethany L., Oikonomou, Vasileios, Aljohani, Amal D., Cheneler, David, Kilic, Volkan, Horzum, Nesrin, Hardy, John G.
Format Journal Article
LanguageEnglish
Published Germany John Wiley & Sons, Inc 01.08.2023
John Wiley and Sons Inc
Wiley
Subjects
aging
Arrays
CAD
Cancer
Computer aided design
Diabetes
Diabetes mellitus
Drug delivery
Drug delivery systems
Hydrogels
Mechanical properties
Mechanics
Metformin
microneedles
Needles
Polyhydroxyethyl methacrylate
Polymers
Skin
Swelling
Temperature
Temperature dependence
microneedles
cancer
hydrogels
aging
drug delivery
diabetes
Online AccessGet full text

Cover

More Information
Summary:The release of metformin, a drug used in the treatment of cancer and diabetes, from poly(2‐hydroxyethyl methacrylate), pHEMA, hydrogel‐based microneedle patches is demonstrated in vitro. Tuning the composition of the pHEMA hydrogels enables preparation of robust microneedle patches with mechanical properties such that they would penetrate skin (insertion force of a single microneedle to be ≈40 N). Swelling experiments conducted at 20, 35, and 60 °C show temperature‐dependent degrees of swelling and diffusion kinetics. Drug release from the pHEMA hydrogel‐based microneedles is fitted to various models (e.g., zero order, first order, second order). Such pHEMA microneedles have potential application for transdermal delivery of metformin for the treatment of aging, cancer, diabetes, etc. Microneedle arrays are minimally invasive drug delivery devices that can be designed to deliver a variety of payloads the skin and other targets. Here, their application for the release of metformin in vitro is reported, which may combat aging, cancer, diabetes, etc.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2056-6646
2056-6646
DOI:10.1002/gch2.202300002